Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 7/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 6/20 | 0.49 |
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7449364 | 0.92 | PLK1 (0.52) | PLK1HTR1DNR1H4MAPK14L3MBTL1 | |
| SCHEMBL7450212 | 0.92 | MAPK14 (0.57) | PLK1HTR1DNR1H4MAPK14L3MBTL1 | |
| SCHEMBL5123823 | 0.88 | MAPK14 (0.57) | PLK1HTR1DNR1H4MAPK14L3MBTL1 | |
| SCHEMBL7445617 | 0.88 | PLK1 (0.51) | PLK1HTR1DMAPK14L3MBTL1HTR1B | |
| SCHEMBL6926831 | 0.88 | PLK1 (0.51) | PLK1HTR1DMAPK14L3MBTL1HTR1B | |
| SCHEMBL25382773 | 0.86 | SRD5A2 (0.51) | PLK1NR1H4MAPK14L3MBTL1RARA | |
| SCHEMBL27222321 | 0.86 | PLK1 (0.50) | PLK1NR1H4MAPK14L3MBTL1HSD17B10 | |
| Hydrochloric Acid SCHEMBL38666104 | 0.86 | HTR1D (0.52) | PLK1HTR1DMAPK14L3MBTL1HTR1B | |
| SCHEMBL38665653 | 0.85 | L3MBTL1 (0.65) | PLK1HTR1DNR1H4MAPK14L3MBTL1 | |
| SCHEMBL7441070 | 0.85 | PLK1 (0.49) | PLK1HTR1DNR1H4MAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614247-B2 | Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20060100270-A1 | Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2006-05-11 | — | — | US | disclosed |
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
| WO-2004089348-A2 | USE OF A SEROTONIN TRANSPORTER INHIBITOR FOR THE TREATMENT OF PULMONARY HYPERTENSION | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2004-10-21 | — | — | WO | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-08 | — | — | US | disclosed |
| EP-1368344-A1 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USES IN THERAPY (5HT1B RECEPTOR ACTIVITY) | SMITHKLINE BEECHAM PLC (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| EP-1001766-B1 | COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-5510350-A | USEFUL IN TREATMENT OR PROPHYLAXIS OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
| WO-1995032967-A1 | AMIDE DERIVATIVES HAVING 5HT1D-ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995030675-A1 | BIPHENYLCARBOXAMIDES USEFUL AS 5-HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995017398-A1 | INDOLE, INDOLINE AND QUINOLINE DERIVATIVES WITH 5HT1D (ANTI-DEPRESSIVE) ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017401-A1 | DYHYDROBENZOFURANYL-BIPHENYL CARBOXAMIDES HAVING 5HT1D ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995011243-A1 | BENZANILIDE DERIVATIVES AS 5HT-1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-27 | — | — | WO | disclosed |
| WO-1995006637-A1 | INDOLE AND INDOLINE DERIVATIVES AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-03-09 | — | — | WO | disclosed |
| US-5340810-A | Useful in the treatment and prophylaxis of depression and other disorders of the central nervous system | GLAXO GROUP LIMITED (GB) | 1994-08-23 | — | — | US | disclosed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | PLK1 126/4885HTR1D 1697/4885NR1H4 525/4885 |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | PLK1 2939/4885HTR1D 2/4885NR1H4 1946/4885 |
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SIGMAR1, HTR6, OPRL1 | PLK1 4471/4885HTR1D 44/4885NR1H4 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.